These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

980 related items for PubMed ID: 18927529

  • 1. Is there a place for postmenopausal hormone therapy use in women with lupus?
    Gompel A, Piette JC.
    Panminerva Med; 2008 Sep; 50(3):247-54. PubMed ID: 18927529
    [Abstract] [Full Text] [Related]

  • 2. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM, Naftolin F, Brinton EA, Judelson DR.
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [Abstract] [Full Text] [Related]

  • 3. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA.
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [Abstract] [Full Text] [Related]

  • 4. Postmenopausal hormone therapy: cardiovascular risks.
    Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
    [Abstract] [Full Text] [Related]

  • 5. Systemic lupus erythematosus and hormone replacement therapy.
    Gompel A, Piette JC.
    Menopause Int; 2007 Jun; 13(2):65-70. PubMed ID: 17540136
    [Abstract] [Full Text] [Related]

  • 6. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [Abstract] [Full Text] [Related]

  • 7. Recent epidemiological evidence relevant to the clinical management of the menopause.
    Shapiro S.
    Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666
    [Abstract] [Full Text] [Related]

  • 8. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR, TREAT.
    Maturitas; 2005 Sep 16; 52(1):1-10. PubMed ID: 15963666
    [Abstract] [Full Text] [Related]

  • 9. A comparative review of the risks and benefits of hormone replacement therapy regimens.
    Warren MP.
    Am J Obstet Gynecol; 2004 Apr 16; 190(4):1141-67. PubMed ID: 15118656
    [Abstract] [Full Text] [Related]

  • 10. Indications for hormone therapy: the post-Women's Health Initiative era.
    Reed SD, Newton KM, Lacroix AZ.
    Endocrinol Metab Clin North Am; 2004 Dec 16; 33(4):691-715. PubMed ID: 15501641
    [Abstract] [Full Text] [Related]

  • 11. Postmenopausal hormone therapy: new questions and the case for new clinical trials.
    Manson JE, Bassuk SS, Harman SM, Brinton EA, Cedars MI, Lobo R, Merriam GR, Miller VM, Naftolin F, Santoro N.
    Menopause; 2006 Dec 16; 13(1):139-47. PubMed ID: 16607110
    [Abstract] [Full Text] [Related]

  • 12. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E, Canfell K.
    Am J Epidemiol; 2009 Jul 01; 170(1):24-8. PubMed ID: 19468078
    [Abstract] [Full Text] [Related]

  • 13. Postmenopausal hormone therapy: from monkey glands to transdermal patches.
    Davis SR, Dinatale I, Rivera-Woll L, Davison S.
    J Endocrinol; 2005 May 01; 185(2):207-22. PubMed ID: 15845914
    [Abstract] [Full Text] [Related]

  • 14. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women.
    Rosano GM, Maffei S, Andreassi MG, Vitale C, Vassalle C, Gambacciani M, Stramba-Badiale M, Mercuro G.
    J Cardiovasc Med (Hagerstown); 2009 Jan 01; 10(1):85-92. PubMed ID: 19145119
    [Abstract] [Full Text] [Related]

  • 15. WHI risks: any relevance to menopause management?
    Burger HG.
    Maturitas; 2007 May 20; 57(1):6-10. PubMed ID: 17368974
    [Abstract] [Full Text] [Related]

  • 16. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD.
    Ann N Y Acad Sci; 2005 Jun 20; 1052():57-74. PubMed ID: 16024751
    [Abstract] [Full Text] [Related]

  • 17. Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?
    Salpeter S.
    Climacteric; 2005 Dec 20; 8(4):307-10. PubMed ID: 16390764
    [Abstract] [Full Text] [Related]

  • 18. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?
    Shulman LP.
    J Fam Pract; 2004 Jul 20; Suppl():S13-7. PubMed ID: 15251108
    [No Abstract] [Full Text] [Related]

  • 19. Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer.
    La Vecchia C.
    Breast; 2004 Dec 20; 13(6):515-8. PubMed ID: 15563861
    [Abstract] [Full Text] [Related]

  • 20. Benefits and risks of long-term low-dose oral continuous combined hormone therapy.
    van de Weijer PH, Mattsson LA, Ylikorkala O.
    Maturitas; 2007 Mar 20; 56(3):231-48. PubMed ID: 17034966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.